Search the Newsreel

Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year

Relay Therapeutics (RLAY), a clinical-stage precision medicines company in targeted oncology with a $4.4 billion market cap, has seen its stock surge by 486% over the past year, trading near a new 3-year high. While technical momentum is strong with a 100% "Buy" opinion …

Relay Therapeutics, Inc. $RLAY Shares Bought by California State Teachers Retirement System

California State Teachers Retirement System increased its stake in Relay Therapeutics (NASDAQ:RLAY) by 47.9% in the first quarter, now owning 174,099 shares valued at $1.73 million. Despite institutional ownership of nearly 97%, the company missed analyst expectations on its last quarterly earnings and revenue. …

Blueport Acquisition Ltd (BPAC) posts Q2 2026 results and signs $1.2B SINGAUTO merger

These Analysts Think Relay Therapeutics, Inc.'s (NASDAQ:RLAY) Sales Are Under Threat

Analysts have downgraded their revenue forecasts for Relay Therapeutics (RLAY) for 2026, cutting estimates from US$12m to US$11m and expecting increased losses per share to US$1.60. Despite the lowered outlook, the consensus price target remains unchanged at US$26.77, suggesting that the weaker earnings are …

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Relay Therapeutics, Inc. (NASDAQ:RLAY) recently released its second-quarter results, showing revenue of US$350k, 56% less than analysts expected, and losses of US$0.41 per share, which were larger than modeled. Following these results, analysts have cut their 2026 revenue estimates to US$10.2m and increased their …

Relay Therapeutics (RLAY): Perceptive Advisors discloses 6.4% ownership stake

Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have disclosed a beneficial ownership of 6.4% in Relay Therapeutics, Inc. This stake, totaling 14,106,187 shares, is held directly by the Master Fund. All reporting persons share voting and dispositive power over …

Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Reported And Analysts Have Been Cutting Their Estimates

The user provided an incomplete article content ("Document") and thus a meaningful summary cannot be generated. Similarly, the cleaned content cannot be provided as the full article text is missing.

Citizens Jmp Increases Relay Therapeutics (NASDAQ:RLAY) Price Target to $26.00

Citizens raises Relay Therapeutics stock price target on progress

Citizens has increased its price target for Relay Therapeutics (NASDAQ:RLAY) shares to $26.00 from $21.00, maintaining a Market Outperform rating, based on significant progress in breast cancer treatment development. The company's stock has shown strong performance, surging 514% over the past year, and its …

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Rating of "Moderate Buy" from Brokerages

Relay Therapeutics, Inc. (NASDAQ:RLAY) has received a "Moderate Buy" consensus rating from 14 analysts, with an average 12-month price target of $25.17, exceeding its current share price of $19.77. Despite recent positive analyst actions like price target increases, the company missed its latest quarterly …

2 Things Relay Therapeutics (RLAY) Results Say About Its 4.9x P B Valuation

Relay Therapeutics reported a wider net loss and lower revenue in Q2 2026, leading to a slight pullback in its shares recently, though the stock has seen significant year-to-date gains. The company's P/B ratio of 4.9x is below its peers but still considered expensive …

Relay Therapeutics (NASDAQ:RLAY) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Relay Therapeutics (NASDAQ:RLAY) reported a quarterly loss of $0.41 per share, missing analysts' estimates by $0.02, with revenue of $0.35 million falling short of the $0.96 million consensus. Despite missing estimates, shares rose to $19.77, near its 52-week high, and analysts maintain a "Moderate …

Relay Therapeutics (RLAY) Stock Faces Cash Burn Pressure Despite Flat Reaction

Relay Therapeutics (RLAY) saw its stock tick up slightly after Q2 2026 earnings, but the company continues to face significant cash burn pressure with a net loss of US$83.7 million and minimal revenue. Despite a recent US$300 million equity raise providing a strong cash …

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

Relay Therapeutics announced its second-quarter 2026 financial results and corporate updates, highlighting progress in its zovegalisib program for breast cancer and vascular anomalies. The company selected a triplet regimen for first-line breast cancer, with a Phase 3 trial expected in early 2027, and presented …

FMR LLC (RLAY) discloses 21.27M-share, 10% holding in Relay Therapeutics

FMR LLC has filed an amended Schedule 13G, disclosing a significant 10.0% ownership stake in Relay Therapeutics, Inc. (RLAY), totaling 21,270,751.24 shares of common stock as of July 31, 2026. The filing indicates FMR LLC holds sole voting power over 21,153,779 shares and sole …

Relay Therapeutics, Inc. Stock 12‑Month Price Target Raised to $26.31, Implies 33% Upside

The average 12-month price target for Relay Therapeutics, Inc. (RLAY) stock has increased to $26.31 from $26.08, based on estimates from 13 analysts. This new target suggests a potential upside of approximately 33% from its Aug. 6 closing price. The consensus rating from 14 …

Relay Therapeutics Q2 Results: Sales drop 48% YoY, miss estimates

Relay Therapeutics reported a significant miss on its Q2 analyst estimates, with EPS of $(0.41) against an expected $(0.39). Sales plummeted 48.30% year-over-year to $350,000, falling short of the $872,727 estimate by nearly 60%. This performance indicates considerable top-line pressure and highlights operational challenges, …

Earnings Flash (RLAY) Relay Therapeutics Posts Q2 Loss $0.41 per Share, vs. FactSet Est of $0.39 Loss

Relay Therapeutics (RLAY) reported a Q2 loss of $0.41 per share, which is higher than FactSet's estimated loss of $0.39 per share. The company also announced Q2 revenue of $400,000. Relay Therapeutics is a clinical-stage precision medicine company focused on developing therapies for cancer …

Relay Therapeutics Q2 2026 earnings: Clinical spending rises with cash runway into 2029

Relay Therapeutics reported Q2 2026 revenue of $0.4 million, a decrease from the previous year, with a net loss of $83.7 million due to increased spending on clinical trials. Despite the wider loss, a May equity offering boosted cash reserves to $910.9 million, providing …

Earnings Flash (RLAY) Relay Therapeutics, Inc. Reports Q2 Revenue $400,000

Relay Therapeutics, Inc. (RLAY) announced its Q2 revenue of $400,000. This news follows another report indicating the company posted a Q2 loss of $0.41 per share, which was higher than FactSet's estimate of a $0.39 loss. The company is a clinical-stage precision medicine firm …

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

Relay Therapeutics, Inc. (RLAY) reported a Q2 loss of $0.41 per share, meeting the Zacks Consensus Estimate but missing revenue estimates significantly at $0.35 million. Despite underperforming revenue expectations over the last four quarters, the stock has seen a 132.7% increase year-to-date, contrasting with …

Relay Therapeutics Inc (RLAY) News, Articles, Events & Latest Updates

This article compiles recent news and updates for Relay Therapeutics Inc (RLAY), including its Q2 2026 earnings report showing a loss and missed revenue estimates. Other news highlights include an insider stock sale topping $3 million, an AI biotech reporting significant revenue jump, and …

FMR LLC and Abigail Johnson disclose 9.4% Relay Therapeutics (RLAY) ownership in 13G

FMR LLC and Abigail Johnson have disclosed a 9.4% beneficial ownership in Relay Therapeutics (RLAY) through a Schedule 13G filing. This represents 20,015,113.24 shares of common stock as of June 30, 2026. FMR LLC holds sole voting power over 19,967,458 shares and sole dispositive …

RLAY (RLAY) insider schedules 42,225-share sale after recent stock disposals

Relay Therapeutics (RLAY) insider Sekar Kathiresan has filed to sell 42,225 shares of common stock on August 4, 2026, with an estimated value of $826,465.70, in connection with a stock option exercise. This planned sale follows several recent disposals by Kathiresan in July 2026, …

J.P. Morgan Maintains Relay Therapeutics(RLAY.US) With Buy Rating

J.P. Morgan has reiterated its Buy rating for Relay Therapeutics (RLAY.US). This indicates a continued positive outlook from the investment bank regarding the company's stock.

RLAY (RLAY) filer Sekar Kathiresan plans 30,000-share sale after option exercise

Sekar Kathiresan, a reporting person for Relay Therapeutics (RLAY), has filed to sell 30,000 shares of common stock around July 31, 2026, for an indicated value of $563,553. This planned transaction is linked to a stock option exercise. The filing also reports two recent …

Is Relay Therapeutics (RLAY) Turning Zovegalisib Updates Into a Credibility Test for Its Pipeline Strategy?

Relay Therapeutics is nearing its Q2 2026 earnings report, with significant investor attention on updates for its lead asset, zovegalisib, and other pipeline programs. Analysts are increasingly optimistic, anticipating strong earnings and progress in oncology and genetic disease trials. The company recently completed a …

Relay Therapeutics to report Q2 2026 results on Aug 6

Relay Therapeutics, Inc. (NASDAQ: RLAY) will announce its second-quarter 2026 financial results and corporate highlights after U.S. financial markets close on August 6, 2026. The clinical-stage precision medicine company focuses on developing therapies for cancer and genetic diseases, with its lead asset, zovegalisib, currently …

Relay Therapeutics (RLAY) CFO sells 1,459 shares to cover taxes

Relay Therapeutics' CFO, Thomas Catinazzo, sold 1,459 shares of common stock at $18.61 per share on July 28, 2026. This transaction was solely to cover income tax withholding obligations from the vesting of 3,269 Restricted Stock Units (RSUs) and was conducted without his discretion, …

Relay Therapeutics to report Q2 results after markets close

Relay Therapeutics is scheduled to release its second-quarter 2026 financial results and provide a corporate update on August 6, 2026, after the U.S. market closes. This information was originally published by Relay Therapeutics Inc. via GlobeNewswire. The news brief was generated by Public Technologies …

Relay Therapeutics, Inc. (RLAY) insider sale covers RSU tax

Relay Therapeutics, Inc. President of R&D, Donald A. Bergstrom, sold 2,237 shares of common stock on July 28, 2026, at $18.61 per share. This sale was explicitly to cover income tax withholding obligations from the vesting of 5,012 Restricted Stock Units (RSUs) on July …

Relay Therapeutics schedules its next financial update for Aug. 6

Relay Therapeutics (Nasdaq: RLAY) will report its second quarter 2026 financial results and corporate highlights after the U.S. market closes on Thursday, August 6, 2026. This announcement from the clinical-stage small molecule precision medicine company provides investors and analysts with the upcoming earnings date. …